Navigation Links
Asia Pacific Pharma Companies Turning to High-Risk, High-Reward Drug Development, According to New Report from Thomson Reuters
Date:11/2/2010

PHILADELPHIA and LONDON, Nov. 3, 2010 /PRNewswire/ -- Pharmaceutical companies in the Asia Pacific region are increasingly adapting their business models from the production of generic drugs towards more high-risk, high-return research and development, according to a new report released today by CMR International, a Thomson Reuters business.

The changing picture is seen in the first edition of the 2010 Asia Pacific R&D Factbook, which finds increased clinical trial activity, patent challenges, and molecular development in the region.

"Whilst the proportion of global R&D expenditure allocated to Asia Pacific was less than 1 percent in 2009, these trends show a growing focus on these activities," said Hans Poulsen, head of life sciences consulting at Thomson Reuters.

Global figures for clinical trial recruitment highlight a dramatic shift away from the United States and toward Asia Pacific.  In 2002, 53 percent of patients recruited globally were in North America; in 2008 that figure was down to 32 percent.  Asia Pacific saw an increase from 6 percent to 11 percent over the same period, while Europe showed marginal growth from 14 percent to 17 percent.

Meanwhile, the number of new molecules in development by generic companies, particularly in India, reflects a strong inclination to invest in R&D.  

And the number of patent challenges in the region indicates an increasingly aggressive approach to securing market share. Patent challenges raised by Indian companies, for example, increased 60 percent from 2006 to 2009, underlining the shifting business model in the region.

"The benefits to Asia Pacific in moving towards increased clinical trials and more drug development are clear: attracting more investment to the local pharma industry, and earlier access to innovative medicines for the local population," Hans Poulsen said. "It is not clear however, if this trend will be seen as an opportunity for collaboration, or an increase in competition for multinational companies."

When it comes to clinical development activities in Asia Pac, location matters. The Factbook reports that Thailand is top for patient recruitment and quality, while Malaysia comes last, and Japan is top for regulatory performance while China is bottom.

The information published in the Factbook is based on primary sources covering major pharmaceutical companies which account for approximately 80 percent of the industry's global R&D expenditure.

For further information, please go to: http://cmr.thomsonreuters.com/services/factbook.  

About CMR International

CMR International, a Thomson Reuters business, is the world leader in global pharmaceutical R&D performance measurement. For almost 15 years, CMR International has worked with the leading global pharmaceutical companies to assess R&D productivity and provide insights into industry trends in order to strengthen planning and effectiveness of R&D. Since 2003, CMR International has published the pharmaceutical R&D Factbook, an annual report for the pharmaceutical R&D sector providing a reliable source of key reference metrics.

Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals.  We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization.  With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs 55,000 people and operates in over 100 countries.  For more information, go to www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Accuray Hires General Manager for the Asia Pacific Region
2. PAREXEL Opens New Office in Japan and Further Strengthens Leading Presence in Asia/Pacific Region
3. Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum
4. PAREXEL Announces Strategic Functional Service Provider Relationship with Eli Lilly and Company for Clinical Development in Asia/Pacific Region
5. American Pacific Adopts Corporate Governance Changes
6. Reportlinker Adds Pharmaceutical M&A in the Asia-Pacific Region - India and China drive regional activity but Japan still dominates high value transactions
7. Codexis to Present at the Pacific Crest Technology Leadership Forum
8. CSafe Signs Master Lease With Cathay Pacific Airways to Further Enhance Healthcare and Pharmaceutical Transport
9. Pacific Bridge Medical to Host Taiwan Drug Registration Webinar
10. Swedish Cancer Institute and Elekta Launch Renewed Partnership Agreement to Continue the Flow of World-Class Technology, Services to Cancer Patients in the Pacific Northwest and Beyond
11. American Pacific to Release Financial Results and Hold Fiscal 2010 Second Quarter Investor Teleconference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 ... Review, H1 2016" is a report that provides ... helps strengthen R&D pipelines by identifying new targets ... Company Profiles discussed in this H1 ... Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., ...
(Date:4/27/2016)... Italy , April 27, 2016 ... linear accelerator (MR-linac) platform will be the focal point ... meeting of the European Society for Radiotherapy & Oncology, ... Elekta,s MR-linac integrates a state-of-the-art radiotherapy system and a ... physician to clearly see the patient,s anatomy in real ...
(Date:4/27/2016)... April 27, 2016 Shire plc (LSE: ... Poulton , Chief Financial Officer, will present at the Deutsche ... MA on Wednesday, May 04, 2016, 10:00 am ... be available on the Presentations and Webcasts section of Shire,s ... the webcast will be available on this same website for ...
Breaking Medicine Technology:
(Date:4/29/2016)... , ... April 29, 2016 , ... ... loans more flexibility in repaying their loans, more information about their loan terms ... when total outstanding student loan debt, including federal and private loans, has reached ...
(Date:4/29/2016)... Petersburg, Fla. (PRWEB) , ... April 29, 2016 ... ... Children’s Hospital surgeon reveals that infants born with severe congenital diaphragmatic hernia have ... babies is born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails ...
(Date:4/29/2016)... ... April 29, 2016 , ... Mobility Designed is redefining mobility with ... armpits, the M+D Crutch evenly distributes body weight from the elbow to the forearm. ... using the crutches than with other crutches. , Co-founders Max and Liliana Younger were ...
(Date:4/29/2016)... ... , ... Melanoma is the deadliest type of skin cancer. Although only about 1 percent of ... deaths. More than 10,000 people are expected to die of melanoma this year. The risk ... one of the most commonly diagnosed cancers in young women. A recent breakthrough in genetic ...
(Date:4/29/2016)... ... , ... Reltok Nasal Products proudly announces that Boston Medical Products, Inc., a ... throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product line. , ... patented safety device secured by nasal surgeons onto the floor of the nasal passages, ...
Breaking Medicine News(10 mins):